Alabama governor signs medical marijuana legalization bill
Late last month, the governor signed another bill that expands expungement eligibility for certain convictions, including misdemeanor marijuana possession.
Drugs & Entheogens
First Phase 3 trial data for MDMA therapy sets path for approval in the U.S.
The extremely promising data are the first Phase 3 results to be revealed for any psychedelic-based therapy, paving the way for a landmark US Food and Drug Administration (FDA) approval in 2023.
New Mexico legalizes recreational cannabis
Home cannabis cultivators can grow up to six plants per person, or 12 plants per household. Police will no longer be able to use the scent of cannabis as grounds for arrest.
MDMA proves a promising alcoholism treatment in world-first trial
A small open-label trial is the first to test MDMA therapy as a treatment for addiction and the results suggest it is safe, well-tolerated and significantly more effective than any current treatment for alcoholism.
U.S. counties with more cannabis dispensaries are suffering fewer opioid deaths
A new study out of UC Davis suggests that increased access to cannabis stores that legally sell medical and recreational cannabis may help to reduce opioid-related deaths.
Somerville, Massachusetts decriminalizes naturally occurring psychedelics
The Somerville City Council voted 9-0 to decriminalize the possession of entheogenic plants, including psilocybin mushrooms and ibogaine.
Psychedelic research center launched at New York’s Mount Sinai
Named the Center for Psychedelic Psychotherapy and Trauma Research the institution is first focusing on MDMA-assisted psychotherapy for PTSD.
U.N. reclassifies cannabis as a less dangerous drug
Cannabis is no longer classified as a Schedule IV drug as per WHO’s recommendation. The declassification opens up the door for more research into its medicinal and therapeutic uses.
MDMA-assisted couples therapy shows promising initial results in landmark pilot trial
The new study reports the addition of MDMA to the couples therapy protocol resulted in effects that were, “on par with, or greater than, those achieved with CBCT [cognitive-behavioral conjoint therapy] alone.”
First of-its-kind study suggests psilocybin can help treat migraines
A first-of-its-kind exploratory study, led by researchers from Yale School of Medicine, has found a single dose of the psychedelic psilocybin can reduce migraine frequency by 50 percent for a least two weeks.